Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Insider Sells $36,008.00 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Elyse Stock sold 800 shares of Biohaven Pharmaceutical stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $45.01, for a total value of $36,008.00. Following the sale, the insider now directly owns 800 shares of the company’s stock, valued at approximately $36,008. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

NYSE BHVN opened at $44.97 on Friday. The stock has a 50-day simple moving average of $43.15 and a two-hundred day simple moving average of $48.89. The firm has a market capitalization of $2.33 billion, a P/E ratio of -7.31 and a beta of 0.32. Biohaven Pharmaceutical Holding Co Ltd has a fifty-two week low of $29.17 and a fifty-two week high of $67.86.

Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.09) by ($0.26). Sell-side analysts expect that Biohaven Pharmaceutical Holding Co Ltd will post -7.43 earnings per share for the current year.

A number of analysts have commented on the company. Zacks Investment Research raised Biohaven Pharmaceutical from a “sell” rating to a “buy” rating and set a $48.00 price target for the company in a research report on Tuesday, October 15th. Goldman Sachs Group set a $89.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Oppenheimer set a $67.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Morgan Stanley set a $50.00 price target on Biohaven Pharmaceutical and gave the stock a “hold” rating in a research report on Friday, August 9th. Finally, William Blair reaffirmed a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. Biohaven Pharmaceutical currently has an average rating of “Buy” and an average target price of $69.36.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NJ State Employees Deferred Compensation Plan raised its stake in shares of Biohaven Pharmaceutical by 150.0% during the 3rd quarter. NJ State Employees Deferred Compensation Plan now owns 15,000 shares of the company’s stock valued at $626,000 after buying an additional 9,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Biohaven Pharmaceutical by 16.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,618 shares of the company’s stock valued at $109,000 after buying an additional 362 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Biohaven Pharmaceutical by 511.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $46,000 after buying an additional 920 shares during the last quarter. Canton Hathaway LLC purchased a new position in shares of Biohaven Pharmaceutical during the 3rd quarter valued at about $83,000. Finally, River & Mercantile Asset Management LLP purchased a new position in shares of Biohaven Pharmaceutical during the 2nd quarter valued at about $1,957,000. Institutional investors and hedge funds own 90.93% of the company’s stock.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Story: Monthly Dividend Stocks Can Provide Solid Income

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.